This antibody is widely used in:
Biliary Epithelial Cells (BECs): TFF3 expression in BECs is STAT3-dependent and enhances wound healing by promoting migration. IL-6-deficient BECs show reduced TFF3 and impaired repair, reversible with recombinant TFF3 .
Signaling Pathways: STAT3 activation increases TFF3, while MAPK inhibitors (e.g., PD98059) further elevate TFF3, suggesting therapeutic potential in biliary strictures .
Breast Cancer: Serum TFF3 levels are elevated in breast cancer patients (AUC = 0.72 vs. controls). Immunohistochemistry using TFF3 antibodies shows 73.9% positivity in tumors, correlating with serum levels .
Therapeutic Target: Recombinant TFF3 or analogs may prevent strictures in liver grafts by enhancing epithelial repair .